MedPage Today HIV/AIDS

HIV/AIDS in Practice: The New Drug Pipeline

Sat, 03 Dec 2011 10:00:00 -0400

Clinicians have a range of powerful drugs to treat HIV, but new options are always good to have. In this exclusive Clinical Context report, ALLMedPage Today North American correspondent Michael Smith asked Joe Eron, MD, of the University of North Carolina Chapel Hill to look into his crystal ball at the HIV pipeline.

IDSA: Hep B Vaccine Benefit Persists in HIV Patients

Wed, 26 Oct 2011 13:45:00 -0400

BOSTON -- The effects of the hepatitis B vaccine appeared to last long-term in HIV-infected patients even if they have high CD4-positive cell counts, researchers said here.

IDSA: Risk of Muscle Breakdown in HIV

Wed, 26 Oct 2011 13:00:00 -0400

BOSTON -- The risk for rhabdomyolysis is significantly elevated in HIV-infected patients, according to researchers here.

IDSA: Flu Season Not Any Worse for HIV Patients

Wed, 26 Oct 2011 12:00:00 -0400

BOSTON -- The most recent H1N1 influenza pandemic did not appear to be any rougher on HIV patients than previous seasonal influence epidemics, government researchers said.

IDSA: HIV Patients Face Early Anal Cancer Risk

Tue, 25 Oct 2011 14:45:00 -0400

BOSTON -- Anal intraepithelial neoplasia seems to develop during the first year of HIV infection, according to the results of a cross-sectional study.

IDSA: Young Adult HIV Patients in Hospital More Often

Tue, 25 Oct 2011 12:27:25 -0400

BOSTON -- Adolescents and young adults, ages 17-24, who were perinatally infected with HIV (PHIV) appear to have increased hospitalization rates compared with younger PHIV patients, researchers suggested here.

IDSA: HCV Drug Shows Promise in HIV

Mon, 24 Oct 2011 16:18:00 -0400

BOSTON -- The recently approved hepatitis C drug boceprevir (Victrelis) is effective in patients co-infected with HIV, according to interim results of a phase II study.

IDSA: Heart Check of HIV Patients Finds Blips

Mon, 24 Oct 2011 12:38:10 -0400

BOSTON -- Abnormalities in cardiac function were prevalent among HIV patients, according to a single-center study.

IDSA: Raltegravir Continues to Show Efficacy for HIV Response

Mon, 24 Oct 2011 00:02:00 -0400

BOSTON -- Long-term treatment with raltegravir (Isentress), an HIV-1 integrase inhibitor, appeared to improve outcomes for HIV-infected patients compared with treatment based on efavirenz (Sustiva), researchers said here.

IDSA: Oral Fungi Offer Clue to Candidiasis Therapy

Sun, 23 Oct 2011 09:00:00 -0400

BOSTON -- A study of the oral microbes in healthy and HIV-positive people has led to a new possibility for management of candidiasis, a researcher reported here.

IDSA: Renal Function Okay With Tenofovir

Sat, 22 Oct 2011 17:29:13 -0400

BOSTON -- Treatment of HIV patients with antiretroviral regimens containing tenofovir (Viread) did not appear to significantly affect renal function after one year of therapy compared to other antiretroviral regimens, researchers said here.

IDSA: HIV Testing in High-Risk Group Unchanged

Fri, 21 Oct 2011 19:15:41 -0400

BOSTON -- Despite government guidance encouraging more testing for HIV infection, researchers said here they found no significant increase in testing among men at high risk for acquiring the pathogen that causes AIDS.

HIV/AIDS in Practice: Choosing a First Regimen, a Clinical Context Report

Fri, 21 Oct 2011 15:51:19 -0400

Clinicians faced with starting treatment on a new HIV patient have a number of medications and combinations to choose from. ALLMedPage Today North American Correspondent Michael Smith discusses the options with Cal Cohen, MD, of Harvard Vanguard Medical Associates, in this Clinical Context Report.

HIV Drug Resistance Effect Damped Down over Time

Sun, 09 Oct 2011 18:30:00 -0400

The proportion of HIV patients able to suppress the virus despite extensive drug resistance nearly tripled over a 10-year period, researchers reported.

Depo Contraceptive Increases HIV Risk

Mon, 03 Oct 2011 18:30:00 -0400

Depot medroxyprogesterone acetate injections and other hormonal methods of contraception, including birth control pills, are associated with an increased risk of acquiring HIV for both men and women, researchers reported.